The South Korea Companion Animal Diagnostic Market was valued at $35.6 Million in 2026 and projected to reach to $56.2 Million by 2031, representing a compound annual growth rate of 9.6%. South Korea's companion animal diagnostic market is positioned for sustained growth through 2031, driven by demographic shifts toward pet ownership and elevated consumer willingness to invest in animal healthcare.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea's companion animal diagnostic market is valued at USD 35.6 million in 2026, with projections reaching USD 56.2 million by 2031, representing a 57.9% increase over the forecast period.
South Korea's market grows at 9.6% CAGR, outpacing the global average of 8.7%, indicating stronger regional demand and market maturation compared to international benchmarks.
Rising pet ownership rates in South Korea are driving increased consumer spending on companion animal healthcare, with pet parents prioritizing diagnostic services for preventive and therapeutic care.
South Korea's well-developed veterinary infrastructure and adoption of cutting-edge diagnostic technologies support market expansion and enable rapid integration of innovative testing solutions.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | MOLECULAR DIAGNOSTICS (Technology) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 8.7% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 3.56 (2026) |
| Revenue Forecast (Billions) | ~USD 5.4 (2031) |
| Segments Covered | Product, Technology, Type, Application, Animal Type, End User |
6 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| MINDRAY MEDICAL INTERNATIONAL LIMITED | China | Private Company | Patient Monitoring and Life Support Products,In-Vitro Diagnostic Products,Medical Imaging Systems, |
| QIAGEN NV | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics (incl. TB IGRA, transplant, viral load),Oncology, sexual and reproductive health assays, |
| IDEXX LABORATORIES, INC. | United States | Public Company | Companion Animal Group – in-clinic analyzers and SNAP rapid assays,Companion Animal Group – reference laboratories and telemedicine/consulting,Veterinary software, services, VetConnect PLUS and VetLab Station, |
| FUJIFILM CORPORATION | Japan | Public Company | Healthcare (medical devices, CDMO, pharma, regenerative medicine, cosmetics/supplements),Business Innovation (office equipment, document solutions, graphic communications, inkjet),Electronics (display, semiconductor materials, storage, industrial equipment, fine chemicals), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (culture media, VITEK 2, VITEK MS, AST including ETEST/VITEK REVEAL),Syndromic and molecular diagnostics (BIOFIRE, BIOFIRE SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassays and CLIA (VIDAS, Hybiome), |
| BIONOTE | South Korea | Public Company | Veterinary fluorescence immunoassay and molecular diagnostics,Veterinary clinical biochemistry systems and reagents,Veterinary rapid immunoassay and ELISA kits, |
| VIRBAC | France | Public Company | Companion-animal parasiticides and anti-infectives,Companion-animal specialty therapeutics & behavior (CKD diets, pheromones, mobility),Farm-animal vaccines (swine focus: Suigen range), |
Mindray Medical International Limited is a Chinese medical device manufacturer founded in 1991 with 8,400 employees. Operating as a private company, it specializes in diagnostic and monitoring equipment for healthcare applications.
QIAGEN NV is a Dutch public company founded in 1984 with 5,500 employees. It provides molecular diagnostics, sample preparation, and life sciences research tools globally.
IDEXX Laboratories, Inc. is a United States-based public company founded in 1983 with 11,000 employees. The company develops and manufactures diagnostic equipment and software for veterinary and water testing markets.
Fujifilm Corporation is a Japanese public company founded in 1934 with 73,526 employees. It operates across imaging, diagnostics, pharmaceuticals, and industrial products globally.
Thermo Fisher Scientific Inc. is a United States public company founded in 1956 with 125,000 employees. It is a leading provider of laboratory equipment, reagents, and analytical instruments worldwide.
bioMérieux is a French public company founded in 1963 with 14,894 employees. It specializes in in vitro diagnostics and microbiology testing solutions for clinical and industrial applications.
BioNote is a South Korean public company founded in 2003 with 298 employees. The company develops and manufactures diagnostic devices and reagents for veterinary and clinical use.
Virbac is a French public company founded in 1968 with 6,442 employees. It specializes in veterinary pharmaceuticals and animal health products.
South Korea's companion animal diagnostic market is valued at USD 35.6 million in 2026 and is projected to reach USD 56.2 million by 2031.
South Korea's companion animal diagnostic market is expected to grow at a compound annual growth rate (CAGR) of 9.6% from 2026 to 2031.
Growth in South Korea is driven by rising pet ownership, increased consumer spending on pet healthcare, advanced veterinary infrastructure, and growing awareness of preventive diagnostics.
South Korea shows strong demand for point-of-care testing, imaging diagnostics, laboratory services, and digital diagnostic tools integrated with veterinary management systems.
South Korea's 9.6% CAGR exceeds the global average of 8.7%, reflecting the country's strong pet healthcare market and consumer spending patterns.
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the companion animal diagnostics market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the companion animal diagnostics market. Primary sources from the demand side include R&D product development teams in animal health companies, veterinary clinicians, diagnostic laboratory managers, and procurement heads at veterinary reference laboratories.

Note: C-level executives include CEOs, COOs, CTOs, and VPs. Other designations include sales, marketing, and product managers.
Tiers are defined based on a company’s total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The total size of the companion animal diagnostics market was determined through data triangulation across three approaches, as described below. After each approach, the weighted average of the three was calculated based on the level of assumptions used in each.

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed as applicable to complete the overall market engineering process and obtain exact statistics for all segments and subsegments.
Companion animal diagnostics use plasma, serum, blood, urine, feces, and tissue samples to detect, monitor, and manage diseases and health conditions in dogs, cats, horses, and other household pets. The companion animal diagnostics market includes diagnostic instruments, test kits, reagents, and consumables used in veterinary clinics and laboratories, covering technologies such as clinical chemistry analyzers, hematology analyzers, immunodiagnostics and ELISA test kits, urinalysis systems, molecular diagnostic assays, glucose monitoring systems, and blood gas–electrolyte analyzers. These products support routine wellness screening, disease diagnosis, treatment monitoring, and preventive healthcare in companion animals.
Based on the given market data, MarketsandMarkets offers customization to meet your company’s specific needs. The following customization options are available for the report:
Company Information
Full forecast, segment splits, and company analysis for all Companion Animal Diagnostic Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report